Literature DB >> 28100904

Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer.

Chung-Han Lee1, Robert J Motzer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28100904      PMCID： PMC5573185          DOI： 10.1038/nrneph.2016.194

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  7 in total

1.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

2.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

3.  Targeting renal cell carcinoma with a HIF-2 antagonist.

Authors:  Wenfang Chen; Haley Hill; Alana Christie; Min Soo Kim; Eboni Holloman; Andrea Pavia-Jimenez; Farrah Homayoun; Yuanqing Ma; Nirav Patel; Paul Yell; Guiyang Hao; Qurratulain Yousuf; Allison Joyce; Ivan Pedrosa; Heather Geiger; He Zhang; Jenny Chang; Kevin H Gardner; Richard K Bruick; Catherine Reeves; Tae Hyun Hwang; Kevin Courtney; Eugene Frenkel; Xiankai Sun; Naseem Zojwalla; Tai Wong; James P Rizzi; Eli M Wallace; John A Josey; Yang Xie; Xian-Jin Xie; Payal Kapur; Renée M McKay; James Brugarolas
Journal:  Nature       Date:  2016-09-05       Impact factor: 49.962

4.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Authors:  Alain Ravaud; Robert J Motzer; Hardev S Pandha; Daniel J George; Allan J Pantuck; Anup Patel; Yen-Hwa Chang; Bernard Escudier; Frede Donskov; Ahmed Magheli; Giacomo Carteni; Brigitte Laguerre; Piotr Tomczak; Jan Breza; Paola Gerletti; Mariajose Lechuga; Xun Lin; Jean-Francois Martini; Krishnan Ramaswamy; Michelle Casey; Michael Staehler; Jean-Jacques Patard
Journal:  N Engl J Med       Date:  2016-10-09       Impact factor: 91.245

5.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Naomi B Haas; Judith Manola; Robert G Uzzo; Keith T Flaherty; Christopher G Wood; Christopher Kane; Michael Jewett; Janice P Dutcher; Michael B Atkins; Michael Pins; George Wilding; David Cella; Lynne Wagner; Surena Matin; Timothy M Kuzel; Wade J Sexton; Yu-Ning Wong; Toni K Choueiri; Roberto Pili; Igor Puzanov; Manish Kohli; Walter Stadler; Michael Carducci; Robert Coomes; Robert S DiPaola
Journal:  Lancet       Date:  2016-03-09       Impact factor: 79.321

6.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962

7.  On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.

Authors:  Hyejin Cho; Xinlin Du; James P Rizzi; Ella Liberzon; Abhishek A Chakraborty; Wenhua Gao; Ingrid Carvo; Sabina Signoretti; Richard K Bruick; John A Josey; Eli M Wallace; William G Kaelin
Journal:  Nature       Date:  2016-09-05       Impact factor: 49.962
  7 in total
  11 in total

Review 1.  Non-angiogenic tumours and their influence on cancer biology.

Authors:  Tom Donnem; Andrew R Reynolds; Elizabeth A Kuczynski; Kevin Gatter; Peter B Vermeulen; Robert S Kerbel; Adrian L Harris; Francesco Pezzella
Journal:  Nat Rev Cancer       Date:  2018-03-09       Impact factor: 60.716

Review 2.  Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.

Authors:  John C Chappell; Laura Beth Payne; W Kimryn Rathmell
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

3.  Hypoxia signaling: Challenges and opportunities for cancer therapy.

Authors:  Mircea Ivan; Melissa L Fishel; Oana M Tudoran; Karen E Pollok; Xue Wu; Paul J Smith
Journal:  Semin Cancer Biol       Date:  2021-10-07       Impact factor: 15.707

4.  The predictive value of the preoperative fibrinogen-albumin ratio on the postoperative prognosis of renal cell carcinoma.

Authors:  Jun Liu; Ying Gan; Haifeng Song; Kun Zhu; Qian Zhang
Journal:  Transl Androl Urol       Date:  2020-06

5.  Expanding the miRNA Transcriptome of Human Kidney and Renal Cell Carcinoma.

Authors:  Adam P Sage; Brenda C Minatel; Erin A Marshall; Victor D Martinez; Greg L Stewart; Katey S S Enfield; Wan L Lam
Journal:  Int J Genomics       Date:  2018-07-03       Impact factor: 2.326

Review 6.  Modeling clear cell renal cell carcinoma and therapeutic implications.

Authors:  Melissa M Wolf; W Kimryn Rathmell; Kathryn E Beckermann
Journal:  Oncogene       Date:  2020-03-02       Impact factor: 9.867

7.  Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries.

Authors:  Wen-Wei Sung; Po-Yun Ko; Wen-Jung Chen; Shao-Chuan Wang; Sung-Lang Chen
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

8.  Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma.

Authors:  Wenzhong Zheng; Shiqiang Zhang; Huan Guo; Xiaobao Chen; Zhangcheng Huang; Shaoqin Jiang; Mengqiang Li
Journal:  Cell Commun Signal       Date:  2021-03-24       Impact factor: 5.712

9.  Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study.

Authors:  Wen-Jin Chen; Hao Cao; Jian-Wei Cao; Li Zuo; Fa-Jun Qu; Da Xu; Hao Zhang; Hai-Yi Gong; Jia-Xin Chen; Jian-Qing Ye; Si-Shun Gan; Wang Zhou; Da-Wei Zhu; Xiu-Wu Pan; Xin-Gang Cui
Journal:  Cell Death Dis       Date:  2022-01-11       Impact factor: 8.469

Review 10.  Examining heterogeneity of stromal cells in tumor microenvironment based on pan-cancer single-cell RNA sequencing data.

Authors:  Wenhui Wang; Li Wang; Junjun She; Jun Zhu
Journal:  Cancer Biol Med       Date:  2021-08-17       Impact factor: 4.248
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.